SCHEMBL878745

SCHEMBL878745

COC(c1cccc(N=O)c1)c1c[nH]c2ncc(-c3cccnc3)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK1 Q96PY6 4/20 0.49
KIT P10721 1/20 0.48
DYRK1A Q13627 3/20 0.44
NTRK1 P04629 2/20 0.44
PIK3CA P42336 1/20 0.44
CCNT1 O60563 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CDK9 P50750 1/20 0.42
PDPK1 O15530 1/20 0.41
AAK1 Q2M2I8 4/20 0.40
PLCG1 P19174 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413620 0.84 NEK1 (0.47) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL878636 0.74 NEK1 (0.55) NEK1DYRK1ANTRK1PIK3CACCNT1
SCHEMBL14845841 0.74 HDAC3 (0.48) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL3505412 0.74 HDAC3 (0.48) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL878714 0.73 FGFR1 (0.48) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL878725 0.73 GPR55 (0.45) NEK1KITDYRK1ANTRK1CDK2
SCHEMBL12663601 0.73 DYRK1A (0.52) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL3505410 0.72 NEK1 (0.47) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL7950810 0.72 RIPK1 (0.46) NEK1KITDYRK1ANTRK1PIK3CA
SCHEMBL10283343 0.71 MTNR1B (0.40) NEK1KITDYRK1ANTRK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143271-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-03-27 US disclosed
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022098-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 NEK1 223/4885KIT 1117/4885DYRK1A 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.